Lapatinib Ditosylate
Who holds supplier records for Lapatinib Ditosylate? 8 organisations hold a current record for Lapatinib Ditosylate: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: Taiwan (2), India (2), United States (1), France (1) and 1 other country (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Lapatinib Ditosylate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lapatinib-ditosylate
Reading the evidence
- 8 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Lapatinib Ditosylate expires 18 Sept 2029. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (8)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Lapatinib Ditosylate. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALP PHARM BEIJING CO LTDActive DMF 29712 · latest filing Sept 2015
- CAMBREX CHARLES CITY INCUnited StatesActive DMF 29808 · latest filing Sept 2015
- CHEMWERTH INCFranceActive DMF 34836 · latest filing Feb 2021
- DELMAR CHEMICALS INCCanadaActive DMF 32266 · latest filing Jan 2018
- Formosa Laboratories, Inc.Taiwan Company GMP cert on recordActive DMF 24788 · latest filing Mar 2011
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 27602 · latest filing Oct 2013
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 35214 · latest filing Feb 2021
- SCINOPHARM TAIWAN LTDTaiwanActive DMF 30043 · latest filing Dec 2015
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Lapatinib Ditosylate are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- India · Inactive DMF 36602 · filed Jan 2022
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (3 listed products contain Lapatinib Ditosylate). The latest listed patent expires 18 Sept 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Lapatinib Ditosylate is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1201179).
Chemical identity
- IUPAC name
- N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;bis(4-methylbenzenesulfonic acid);hydrate
- Canonical SMILES
- CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.O
- InChIKey
- XNRVGTHNYCNCFF-UHFFFAOYSA-N
- Synonyms
- GW-572016F, GW572016F, Lapatinib ditoluenesulfonate monohydrate, Lapatinib ditosylate, Lapatinib ditosylate anhydrous, Lapatinib ditosylate monohydrate, Lapatinib tosilate, Lapatinib tosilate hydrate, Tycerb, Tykerb, Tyverb, RefChem:55454
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Protein Kinase Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Lapatinib Ditosylate?
8 organisations hold an active US FDA Type II Drug Master File or a CEP for Lapatinib Ditosylate: ALP PHARM BEIJING CO LTD, CAMBREX CHARLES CITY INC (United States), CHEMWERTH INC (France), DELMAR CHEMICALS INC (Canada), Formosa Laboratories, Inc. (Taiwan), Hetero Labs Limited (India), MSN Laboratories Private Limited (India) and SCINOPHARM TAIWAN LTD (Taiwan). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Lapatinib Ditosylate Drug Master Files are active?
ALP PHARM BEIJING CO LTD (DMF 29712), CAMBREX CHARLES CITY INC (DMF 29808), CHEMWERTH INC (DMF 34836), DELMAR CHEMICALS INC (DMF 32266), Formosa Laboratories, Inc. (DMF 24788), Hetero Labs Limited (DMF 27602), MSN Laboratories Private Limited (DMF 35214) and SCINOPHARM TAIWAN LTD (DMF 30043). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Lapatinib Ditosylate records mean?
1 organisation has only inactive Type II DMFs for Lapatinib Ditosylate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Lapatinib Ditosylate?
Yes. The latest patent listed for an approved US product containing Lapatinib Ditosylate expires 18 Sept 2029, across 3 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Lapatinib Ditosylate supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Lapatinib Ditosylate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.